MG
STSA

Michael Gelband’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Michael Gelband’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,474
Closed -$95K – 2828
2021
Q2 		$95K Buy
+13,474
New +$72.6K ﹤0.01% 2149

Other funds holding STSA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Michael Gelband's STSA Position: Q3 2021 in Review

Michael Gelband sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q3 2021, closing a stake of 13,474 shares — an estimated $95K sold.

Michael Gelband first reported a position in STSA in Q2 2021 and held it in 1 quarter. The position peaked at $95K in Q2 2021. 45 funds tracked by Wall St. Rank hold STSA as of Q3 2021.

  • Michael Gelband reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Michael Gelband sold 13,474 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $95K.
  • Michael Gelband first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Michael Gelband's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $95K in Q2 2021.
  • 45 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on ExodusPoint Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.